Incorporating preauthorization into antimicrobial stewardship pharmacist workflow reducesClostridioides difficileand gastrointestinal panel testing
Authors:
- 1 October 2020
- journal article
- research article
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 41 (10) , 1136-1141
Abstract
Objective: To evaluate whether incorporating mandatory prior authorization forClostridioides difficiletesting into antimicrobial stewardship pharmacist workflow could reduce testing in patients with alternative etiologies for diarrhea. Design: Single center, quasi-experimental before-and-after study. Setting: Tertiary-care, academic medical center in Ann Arbor, Michigan. Patients: Adult and pediatric patients admitted between September 11, 2019 and December 10, 2019 were included if they had an order placed for 1 of the following: (1)C. difficileenzyme immunoassay (EIA) in patients hospitalized >72 hours and received laxatives, oral contrast, or initiated tube feeds within the prior 48 hours, (2) repeat molecular multiplex gastrointestinal pathogen panel (GIPAN) testing, or (3) GIPAN testing in patients hospitalized >72 hours. Intervention: A best-practice alert prompting prior authorization by the antimicrobial stewardship program (ASP) for EIA or GIPAN testing was implemented. Approval required the provider to page the ASP pharmacist and discuss rationale for testing. The provider could not proceed with the order if ASP approval was not obtained. Results: An average of 2.5 requests per day were received over the 3-month intervention period. The weekly rate of EIA and GIPAN orders per 1,000 patient days decreased significantly from 6.05 +/- 0.94 to 4.87 +/- 0.78 (IRR, 0.72; 95% CI, 0.56-0.93;P= .010) and from 1.72 +/- 0.37 to 0.89 +/- 0.29 (IRR, 0.53; 95% CI, 0.37-0.77;P= .001), respectively. Conclusions: We identified an efficient, effectiveC. difficileand GIPAN diagnostic stewardship approval model.Keywords
This publication has 13 references indexed in Scilit:
- Diagnostic stewardship of C. difficile testing: a quasi-experimental antimicrobial stewardship studyInfection Control & Hospital Epidemiology, 2019
- 177. Use of Electronic Best Practice Alert (BPA) to Reduce Inappropriate Testing for Clostridium difficile infection (CDI) at a Tertiary Care CenterOpen Forum Infectious Diseases, 2018
- Understanding Clostridium difficile ColonizationClinical Microbiology Reviews, 2018
- Reductions in Clostridium difficile Infection (CDI) Rates Using Real-Time Automated Clinical Criteria Verification to Enforce Appropriate TestingInfection Control & Hospital Epidemiology, 2018
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)Clinical Infectious Diseases, 2018
- Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infectionJournal of Antimicrobial Chemotherapy, 2017
- ID Learning Unit: Understanding and Interpreting Testing for Clostridium difficileOpen Forum Infectious Diseases, 2014
- Both Oral Metronidazole and Oral Vancomycin Promote Persistent Overgrowth of Vancomycin-Resistant Enterococci during Treatment of Clostridium difficile -Associated DiseaseAntimicrobial Agents and Chemotherapy, 2008
- Object-Oriented Computation of Sandwich EstimatorsJournal of Statistical Software, 2006
- Econometric Computing with HC and HAC Covariance Matrix EstimatorsJournal of Statistical Software, 2004